Zobrazeno 1 - 10
of 1 960
pro vyhledávání: '"Barbachano, Y"'
Autor:
Signorovitch J; Analysis Group, Boston, USA., Zhang J; US Food and Drug Administration, Silver Spring, USA., Brown D; UK Medicines & Healthcare Products Regulatory Agency, London, UK., Dunnmon P; Janssen Research & Development, Raritan, USA., Xiu L; Janssen Research & Development, Raritan, USA., Done N; Analysis Group, Boston, USA., Hsu K; Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA., Barbachano Y; UK Medicines & Healthcare Products Regulatory Agency, London, UK., Lousada I; Amyloidosis Research Consortium, 320 Nevada Street, Suite 210, Newton, MA, 02460, USA. ILousada@arci.org.
Publikováno v:
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2024 Jul; Vol. 58 (4), pp. 600-609. Date of Electronic Publication: 2024 Apr 17.
Autor:
Starling, N. †, Hawkes, E.A. †, Chau, I., Watkins, D., Thomas, J., Webb, J., Brown, G., Thomas, K., Barbachano, Y., Oates, J., Cunningham, D. *
Publikováno v:
In Annals of Oncology April 2012 23(4):942-947
Autor:
Wong, R., Cunningham, D. *, Barbachano, Y., Saffery, C., Valle, J., Hickish, T., Mudan, S., Brown, G., Khan, A., Wotherspoon, A., Strimpakos, A.S., Thomas, J., Compton, S., Chua, Y.J., Chau, I.
Publikováno v:
In Annals of Oncology September 2011 22(9):2042-2048
Autor:
Liu L; Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium. Electronic address: limin.liu@ugent.be., Choi J; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands., Musoro JZ; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium., Sauerbrei W; Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany., Amdal CD; Research Support Services, Department of Oncology, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo, Norway., Alanya A; European Organisation for Research and Treatment of Cancer Headquarters, Brussels, Belgium., Barbachano Y; Quanticate, Hitchin, UK., Cappelleri JC; Pfizer, New York, NY, USA., Falk RS; Research Support Services, Department of Oncology, Oslo University Hospital, Oslo, Norway., Fiero MH; US Food and Drug Administration, Washington, DC, USA., Regnault A; Modus Outcomes, Lyon, France., Reijneveld JC; Department of Neurology & Brain Tumor Center, VU University Medical Center, Amsterdam, Netherlands., Sandin R; Pfizer, Stockholm, Sweden., Thomassen D; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands., Roychoudhury S; Pfizer, New York, NY, USA., Goetghebeur E; Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium., le Cessie S; Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Netherlands.
Publikováno v:
The Lancet. Oncology [Lancet Oncol] 2023 May; Vol. 24 (5), pp. e197-e206.
Publikováno v:
In Annals of Oncology May 2010 21(5):1013-1019
Autor:
Bhide, Shreerang A., Davies, Mark, Burke, Kevin, McNair, Helen A., Hansen, Vibeke, Barbachano, Y., El-Hariry, I.A., Newbold, Kate, Harrington, Kevin J., Nutting, Christopher M.
Publikováno v:
In International Journal of Radiation Oncology, Biology, Physics 2010 76(5):1360-1368
Autor:
Sohaib, S.A., Koh, D.M., Barbachano, Y., Parikh, J., Husband, J.E.S., Dearnaley, D.P., Horwich, A., Huddart, R.
Publikováno v:
In Clinical Radiology 2009 64(4):362-367
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University College London, London, UK m.sydes@ucl.ac.uk., Barbachano Y; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Bowman L; MRC Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK., Denwood T; NHS Digital, Leeds, UK., Farmer A; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK., Garfield-Birkbeck S; Trials and Studies Coordinating Centre, National Institute for Health Research Evaluation, Southampton, UK., Gibson M; North West E‑Health (NWEH) Ltd, Manchester, UK., Gulliford MC; King's College London, London, UK.; NIHR Biomedical Research Centre at Guy's and St Thomas' Hospitals London, London, UK., Harrison DA; Intensive Care National Audit & Research Centre (ICNARC), London, UK., Hewitt C; York Trials Unit, Department of Health Sciences, The University of York, York, UK., Logue J; Lancaster University, Lancaster, UK., Navaie W; Health Research Authority, London, UK., Norrie J; Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK., O'Kane M; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Quint JK; Department of Respiratory Epidemiology, Occupational Medicine and Public Health, Imperial College London, London, UK., Rycroft-Malone J; Lancaster University, Lancaster, UK.; NIHR Health Services & Delivery Programme, Southampton, UK., Sheffield J; NIHR Clinical Research Network, University of Leeds, Leeds, UK., Smeeth L; Department of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK., Sullivan F; Division of Population & Behavioural Science, University of St. Andrews, St Andrews, UK.; Department of Family & Community Medicine, University of Toronto, Toronto, Ontario, Canada., Tizzard J; Health Research Authority, London, UK., Walker P; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK., Wilding J; Department of Cardiovasular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK., Williamson PR; Department of Health Data Science, University of Liverpool, Liverpool, UK., Landray M; Nuffield Department of Population Health, University of Oxford, Oxford, UK.; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Health Data Research UK, University of Oxford, Oxford, UK., Morris A; Health Data Research UK, London, UK., Walker RR; Health Data Research UK, London, UK., Williams HC; University of Nottingham, Nottingham, UK.; Director of the NIHR Health Technology Assessment Programme (2015-2020), Southampton, UK., Valentine J; Clinical Practice Research Datalink, Medicines and Healthcare Products Regulatory Agency, London, UK.
Publikováno v:
BMJ open [BMJ Open] 2021 Jun 16; Vol. 11 (6), pp. e043906. Date of Electronic Publication: 2021 Jun 16.
Autor:
Mitra, A, Bancroft, E, Barbachano, Y, Page, E, Foster, C, Jameson, C, Mitchell, G, Lindeman, G, Stapleton, A, Suthers, G, Evans, D, Cruger, D, Blanco, I, Mercer, C, Kirk, J, Maehle, L, Hodgson, S, Walker, L, Izatt, L, Douglas, F, Tucker, K, Dorkins, H, Clowes, V, Male, A, Donaldson, A
OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1064::836623afbcf88c9b2d75ab2cb8aaf23c
https://doi.org/10.1111/j.1464-410x.2010.09648.x
https://doi.org/10.1111/j.1464-410x.2010.09648.x